PHARMACEUTICAL COMPOSITIONS COMPRISING S-(-)-N-PROPARGYL-1-AMINO INDAN

Abstract: Pharmaceutical compositions for the treatment of a neurological disorder or neurotrauma or for improving memory in a patient, comprising a therapeutically effective amount of S-(-)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof as active ingredient, and a pharmaceutically active carrier. The pharmaceutical compositions are adapted, in particular for treating a neurological disorder or neurotrauma involving damage caused to the central or peripheral nervous system as a result of ischemic damage, stroke, hypoxia or anoxia, neurodegenerative diseases, Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage.

Description: PHARMACEUTICAL COMPOSITIONS COMPRISING S-H-N-PROPARGYL-1-AMINOINDAN FIELD OF THE INVENTION The present invention concerns the novel therapeutical use of S- (-)-N-propargyl- l-aminoindan and pharmaceutically acceptable salts thereof for the treatment of neurological disorders or neurotrauma and for improving memory in a patient. As used herein, the term "neurotrauma " is meant to refer to damage caused to the central and/or peripheral nervous system as a result of ischemic damage such as a stroke, hypoxia or anoxia, neurodegenerative diseases, Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage. BACKGROUND OF THE INVENTION R(-) dcprenyl (also known as L-dcprcnyl), N,α-dimcthyl-N-2- propcnylphencthylamine) is a well-known inhibitor of the B-form of monoaminc oxidase enzyme (hereinafter "MAO-B "). PCT International Application No. W092/17169 describes the activity of R(-) dcprenyl in maintaining, preventing the loss of, or recovering nerve growth function. This publication includes a list of deprenyl-like derivatives that arc suggested to possess similar activities, although no data is given in support of this contention. Included in the list is AGN-1135 which is racemic N-propargyl- 1-aminoindan. In a subsequent article, Tatton, W.G., et ai, J. Neuroscience, 13(9), pp. 4042-4053, (1993) report that the neuroprotcctive activity of dcprenyl is limited to the R(-) cnantiomcr. The S(-) cnantiomcr was 2000 times less active in increasing the survival of axotomized immature rat facial mononeurons. Furthermore, it was demonstrated that neuroprotective activity is associated only with the R-enantiomcrs of propargyl derivatives that possess MAO-B inhibitory activity. Davis et ai, J. Neurochem. Supplement 1, 6 :S60, (1995) (recording the data presented by the same author at the Twenty-sixth Meeting of the American Society for Neuro- chemistry, held in Santa Monica, California, USA on March 5-9, 1995) disclosed that in various models of neuroprotective activity, the R- enantiomers of certain aliphatic N-mcthylpropargylamincs that are selective inhibitors of MAO-B, were more effective in rescuing damaged neurons than their corresponding S-cnantiomers. The development of the work on dcprenyl has led to the belief that the neuroprotective activity docs not involve inhibition of MAO-B, because sub-inhibitory levels of R(-) deprenyl have been observed to. prevent nerve cell death (Tatton, Movement Disorders, 8(1):S2()-S30, ( 1993)). It has been proposed that R(-) dcprenyl is perhaps dependent on interaction with a subtype of MAO-B that possesses extreme sensitivity to R(-) deprenyl. Yu et ai, J. NeuroscL , 63, pp. 1820-1827, (1994) have assessed the activity of R(-)- and S(+)-dcprcnyI and several aliphatic propargylamine derivatives in reversing the noradrenaline depletion in rodents induced by the administration of N-(2-chloroethyl)-N-cthyl-2- bromobenzylaminc (DSP-4). The end-point measured and described as an indication of "neuroprotective activity" was the percent restoration of noradrenaline as compared to untreated controls. In the results described, R(-) deprenyl and several of the higher N-aliphatically substituted propargylamines displayed "neuroprotective activity". S(+) deprenyl was described as acting like the known noradrenaline uptake inhibitor desipra- minc, having a far lower "neuroprotective activity" in comparison with R(-) deprenyl. In summary, S(+) deprenyl was shown to be a superior noradren- aline uptake inhibitor as compared to R(-) deprenyl, yet far inferior in the described measure of "neuro -protective activity". European Patent 436,492 discloses the R(+) enantiomer of N- propargyl-1 -aminoindan (hereinafter referred to as "R(+)PAI") as a selective irreversible inhibitor of MAO-B. Due to this specific activity R(+)PAI has also been proposed for use in the treatment of Parkinson's Disease, memory disorders, dementia (particularly of the Alzheimer's type), depression and hyperactive syndrome in children. U.S. Patents 5,387,612, 5,453,446 and 5,457,133 relate to R(+)PAI and to methods of treating patients suffering from Parkinson's Disease comprising administering R(+)PAI to the patient. In these U.S. patents emphasis is placed on the superior MAO-B inhibitory activity of R(+)PAI as compared to its antipode, the S(-) cnantiomcr of N-propargyl-1-aminoindan (hereinafter referred to as "S(-)PAI"). In in vitro assays R(+)PAI was found to be nearly 7,000. times more active as an inhibitor of MAO-B than S(-)PAI. It was also found in these assays that, whereas R(+)PAI is more than 29 times more selective for MAO-B than MAO-A (the A-form of monoamine oxidase enzyme), S(-)PAI showed no preference to either substrate. This effect was also observed in both acute and chronic in vivo administration. PCT International Application Publication No. WO95/11016 further disclosed that R(+)PAI is active as a "neuroprotective agent". The data therein describes its use in the prevention of NMDA induced cell death in rat cerebellum cells as well as in slowing ncuronal degeneration when administered after crushing the rat optic nerve. No indication is given in this publication as regards the mechanism by which R(+)PAI may exert its "neuroprotective " effect. The use of MAO inhibitors as ncuronal rescue agents in clinical situations where neuronal survival is in jeopardy, might involve the important disadvantage resulitng from their potential cardiovascular side- effects, alone or following drug-drug or drug-food interactions. These side-effects arc attributed to partial or total inhibition of peripheral MAO-A, resulting in excessive concentrations of norepinephrine in the cardiovascular system (see for example, Physicians' Desk Reference 48th Edition, 1994, Medical Economics Data, Montvale, NJ, under Eldepryl). Selective MAO-B inhibitors such as R(-) deprenyl are less prone to compromise the cardiovascular system than the less specific agents such as pargyline or clorgyline, hence the former are probably the safer agents. However, the MAO subtype selectivity of these agents as determined under in vitro conditions tends to decrease dramatically when determined in vivo. Thus, the ratio of the in vitro IC sn values of MAO-A/MAO-B for R(-) deprenyl has been reported by various authors as 400, 247, 360 and 16 (from a compilation by W.Paul and I. Szelenyi, in "Inhibitors of Monoamine Oxidase-B", I. Szelenyi editor, Birkhauscr, Basel, p. 353, 1993), suggesting a safety factor of about 1 0 or more. The recommended daily dose of R(-) deprenyl in human subjects is 1 mg, with 30-40 mg considered as the dose at which cardiovascular function could be compromised (Physicians' Desk Reference supra). Thus, the safety factor in clinical practice is about 3 to 4, as compared to about 400 in experimental systems in vitro. There still exists, therefore, a need for a "neuroprotective agent" that, while being effective is free from the side-effects associated with hitherto known neuroprotectants of the MAO-B inhibitor type. OBJECT OF THE INVENTION It is thus an object of the present invention to provide a method and pharmaceutical compositions for treating CNS or PNS disorders, particularly those associated with neurotrauma, with an agent that possesses neuroprotective activity but docs not display the peripheral side-effects associated with the known MAO-B inhibitors. SUMMARY OF THE INVENTION The present invention, in accordance with one aspect thereof provides a method of treating a patient suffering from a neurological disorder or neurotrauma comprising administering to said patient a therapeutically effective amount of (S)-N-propargyl-l-aminoindan or a pharmaceutically acceptable salt thereof. The invention specifically provides a method of treating a subject afflicted with a neurodegenerative disease, a neurotoxic injury, brain ischemia or a stroke, which method comprises administering to the subject an amount of S(-)-N-propargyl-l-aminoindan or a pharmaceutically acceptable salt thereof. The invention also specifically provides a method of treating a subject afflicted with neural injury following an episode of hypoxia or anoxia, head trauma injury or spinal trauma injury which method comprises administering to the subject an amount of S(-)-N-propargyl- l -aminoindan or a pharmaceutically acceptable salt thereof. The present invention further provides a method of preventing nerve death in a subject which comprises administering to the subject an amount of S(-)-N-propargyl-l -aminoindan or the pharmaceutically acceptable salt thereof. The present invention further provides a method of treating a subject afflicted with a memory disorder which comprises administering to the subject an amount of S(-)-N-propargyl-l -aminoindan or a pharmaceu- tically acceptable salt thereof effective to improve the memory in the subject. In accordance with another aspect, the invention provides a pharmaceutical composition for the treatment of a neurological disorder or neurotrauma or for improving memory in a patient which comprises a therapeutically effective amount of S(-)-N-propargyl-a-aminoindan or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. In accordance with yet another aspect of the present invention, there is provided S-(-)-N-propargyl-l-aminoindan or a pharmaceutically acceptable salt thereof for use as a medicament for the treatment of a neurological disorder or neurotrauma or for improving memory in a patient. In accordance with yet another aspect of the present invention, there is provided the use of S-(-)-N-propargyl-l-aminoindan or a pharmaceutically acceptable salt thereof as active ingredient in the manufacture of medicaments for improving memory in a patient. DETAILED DESCRIPTION OF THE INVENTION S(-)-propargyl-l-aminoindan may be prepared as described in U.S. Patent 5,457,133 and compositions may be prepared in a similar manner to those described in that patent. in the practice of this invention, it is preferable that a pharmaceutically acceptable salt of S(-)-N-propargyl- l-aminoindan is used. Suitable pharmaceutically acceptable salts include, but arc not limited to, the mesylatc, maleatc, fumaratc, tartratc, hydrochloridc, hydrobromide, esylate, p-toluene sulfonatc, benzoatc, acetate, phosphate and sulfate salts. Preferred arc the hydrochloridc, mcsylate, esylate and sulfate salts of S(-)-N- propargyl-l -aminoindan. Most preferably, the pharmaceutically acceptable salt is the mcsylate salt. For the preparation of pharmaceutically acceptable acid addition salts of S(-)PAI, the free base can be reacted with the desired acids in the presence of a suitable solvent by conventional methods. Similarly, an acid addition salt may be converted to the free base form in a known manner. As stated above, the invention provides, in accordance with one aspect thereof, a pharmaceutical composition which comprises a therapeutically effective amount of S(-)-N-propargyl-l-aminoindan or a pharmaceu- tically acceptable salt thereof and a pharmaceutically acceptable carrier. The "therapeutically effective amount" of the S(-)-N-propargyI-l -aminoindan or pharmaceutically acceptable salt thereof may be determined according to methods well known to those skilled in the art. These compositions may be prepared as medicaments to be administered orally, parcnterally, rcctally, or transdcrmally. The preferred dosages of the active ingredient, i.e., S(-)PAI, in the above compositions arc within the following ranges. For oral or suppository formulations, 0.1- 100 mg per dosage unit may be taken daily, and preferably 1-10 mg per dosage unit is taken daily. For injectable formulations, 0.1-100 mg/ml per dosage unit may be taken daily, and preferably 1-10 mg/ml per dosage unit is taken daily. These compositions may be used alone to treat the above-listed disorders, or alternatively, as an adjunct to the conventional treatments. Suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or soft gelatin capsules, sublingual tablets, syrups and suspensions. In one embodiment, the pharmaceutically acceptable carrier is a solid and the pharmaceutical composition is a tablet. The therapeutically effective amount of the active ingredient may be from about 0.1 mg to about 100 mg, preferably from about 1 mg to about 10 mg. In an alternative embodiment, the pharmaceutically acceptable carrier is a liquid and the pharmaceutical composition is an injectable solution. The therapeutically effective amount of the active ingredient may be from about 0.1 mg/ml to about 100 mg/ml, preferably from about 1 mg/ml to about 10 mg/ml. In one embodiment, the dosage form is an infusion. In a further alternative embodiment, the carrier is a gel and the pharmaceutical composition is a suppository. For parentcral administration the invention provides ampoules or vials that include an aqueous or non-aqueous solution or emulsion of the active ingredient. For rectal administration there are provided suppositories with hvdrophilic or hydrophobic vehicles. For topical application as ointments and transdcrmal delivery there arc provided suitable delivery systems as known in the art. The invention will be described in more detail in the following non-limiting Examples. EXAMPLES CHEMICAL EXAMPLES EXAMPLE 1 Di-(S-(-)-N-Propargyl-l-aminoindan) D-tartrate a) Racemic N-propargyl-1 -aminoindan To a mixture of racemic 1-aminoindan (64 g), 15% aqueous sodium hydroxide solution (141 g), water (107 mL) and toluene (192 L) there was added propargyl bcnzcncsulfonate (94.3 g) during 20 minutes at ambient temperature. The resulting mixture was heated to 45°C for 4 hours, at which time the pH was confirmed to be >12 (45% sodium hydroxide added if necessary) and the phases were separated. To the organic phase water (64 mL) was added and the pH was adjusted to 2 with 33% aqueous sulfuric acid. The aqueous phase was separated, diluted with water and mixed with toluene. The pH was adjusted to 6 with 25% aqueous sodium hydroxide and the phases separated. The aqueous phase was extracted again with toluene, ensuring a pH=6. The combined organic layers were concentrated in vacuo to yield 51 g of crude racemic N-propargyl- 1 -aminoindan as a yellow oil. b) Di-(S-(-)-N-propargyl- 1 -aminoindan) D-tartrate To a solution of crude racemic N-propargyl- 1 -aminoindan (46.5 g) in isopropanol (157 mL) at reflux, was added a solution of D-tartaric acid (15.3 g) in water (28 mL). After 1 hour of reflux the mixture was slowly cooled to ambient temperature and the resulting precipitate was isolated by filtration with suction and washed with isopropanol. The crude di- (S-(-)-N propargyl- 1-aminoindan) D-tartratc was recrystallized from 1 L of isopropanol containing 15% of water to yield 26.5 grams of the title compound: m.p. 175- 177°C, [«]„ -34.3° ( 1.5, H 2 0); Anal, calcd. for C 2S H 32 0 6 N,: C, 68.26; H, 6.56; N, 5.69; Found: C, 68.76; H, 6.57; N, 5.61; EXAMPLE 2 S-(-)-N-Propargyl-l-aminoindan mesylate A solution of di-(S-(-)-N-propargyl- 1-aminoindan) D-tartrate (15 g) from Example 1 , and methanesulfonic acid (6 g) in isopropanol (150 ml) was heated to reflux for 30 minutes. The reaction mixture was allowed to cool to room temperature and the resulting precipitate isolated by suction filtration to yield the title compound (11.1 g) with .p. 157°C, [«] D -22°. Anal, calcd. for C 13 H 17 NSO : C, 58.43; H, 6.37; N, 5.24; S, 11.98; Found: C, 58.70; H, 6,39; N, 5.20; S, 11.82. EXAMPLE 3 S-(-)-N-Propargyl-l-aminoindan mesylate To a solution of sodium hydroxide (4.8 g) in water (80 L) was added di-(S-(-)-N-propargyl- 1-aminoindan) D-tartratc from Example 1 and toluene (80 mL). After stirring for 30 minutes, the mixture was filtered through Celite with suction and the organic layer was separated and washed with water. The organic phase was concentrated in vacuo, diluted with isopropanol and reconcentratcd. The residue was dissolved in isopropanol (125 mL) and treated with methanesulfonic acid (11.5 g). The resulting mixture was heated to reflux for 30 minutes, filtered (Celitc) and allowed to cool to ambient temperature. The resulting precipitate was collected by filtration and washed with isopropanol to yield the title compound with identical physical and chemical properties as the product of Example 2. EXAMPLE 4 S-(-)-N-PropargyI-l-aminoindan mesylate The method of Example la was repeated except that S-(-)-l- aminoindan prepared according to Examples 76-80 of US Patent Application Serial No. 08/372,064 (filed January 12, 1995) (Publication No. WO 96/XXXXX) was used instead of racemic 1-aminoindan. The resulting yellow oil (30 grams) was dissolved in 180 ml of isopropanol, 17.7 grams of mcthanc-sulphonic acid were added and the resulting mixture heated to reflux and allowed to cool. The precipitate was isolated by filtration and recrystallizcd from isopropanol with activated charcoal to give the title compound with identical physical and chemical properties as the compound of Example 2. EXAMPLE 5 S-(-)-N-Propargyl-l-aminoindan hydrochloride 12.4g of S-(-)-l-aminoindan and 12.9g of potassium carbonate were added to 95 ml of acetonitrile. The resulting suspension was heated to 60° and 5.6g of propargyl chloride were added dropwise. The mixture was stirred at 60°C for 16 hours, whereafter most of the volatiles were removed by distillation in vacuo. The residue was partitioned between 10% aqueous sodium hydroxide and methylcnc chloride. The organic phase was dried and the solvent removed in vacuo. The residue was flash chromatographed on silica gel, eluting with 40% ethyl acctatc/60% hexane. Fractions containing the free base of the title compound were combined and the solvent replaced by ether. The ethereal solution was treated with gaseous HCI and the resulting precipitate was isolated by suction filtration and recrystallizcd from isopropanol to yield 6.8g of the title compound. The product exhibited [«] D -30.3° (2% ethanol), m.p. 183-5°C. Biological Examples Example 1 Lack of inhibition of MAO activity in vivo by S(-) PAI mesylate Rats (male Spraguc-Dawlcy-dcrived) weighing 250±2 g were treated with one of the cnantiomers or the racemic form of PAI by intrapcritoncal injection (ip) or oral gavagc (po), and decapitated lh or 2h later respectively. Groups of three rates were used for each dose level of substance, and MAO activity determined in brain and liver using the general technique described in Example 19 of US Patent 5,387,612. The amount of protein in each incubation was determined using the Follin-Lowry method, and enzyme activity calculated as n ol of substrate metabolized per hour of incubation for each mg of protein. Activity of MAO in tissues from animals treated with the enantiomers or the racemic form of PAI was expressed as a percentage of the enzyme activity in a group of control animals administered vehicle (water for oral administration, 0 9% saline for ip injection) 5 Results None of the dose levels used produced any obvious behavioral alterations The doses producing 50%, inhibition of MAO-A and MAO-B (IC50) were ι rv calculated from the inhibition curves, and are shown in Table 1 These data reflect the extremely low activity of S(-)PAI mesylate for inhibition of MAO-A and MAO-B, compared to the selectivity of R(+)PAI mesylate for MAO-B inhibition 15 Table 1 IC-50 values (mg kg) for Inhibition of MAO-A and MAO-B by S(-)PAI mesylate, or R(+)PAI mesylate in rat brain and liver following intraperitoneal injection (ip) or oral administration (po) MAO-A MAO-B 0 S(-)PAI mesylate R(+)PAI mesylate S(-)PAI mesylate R(+)PAI mesylate ip brain >10 1 2 >10 0 07 ip liver >10 5 >10 0.06 po brain >10 >5 >10 0 17 po liver >10 >5 >10 0 05 -y Example 2 Neuroprotective effect of S PAI in the hypobaric hvpo-ria model The model used is analogous to the one described by M.Nakanishi et al , Life Sci 13 467-476 0 (1973), and by Y Oshiro et al , J Med Chem 34 2014-2023 (1991) A group of 4 ICR male mice each weighing 20-25 g were placed in a 2 5 L glass chamber (A) at atmospheric pressure Chamber A is connected to a 12 L chamber (B) through a valve which is initially pressure. Chamber A is connected to a 12 L chamber (B) through a valve which is initially closed. The air in chamber B was evacuated to a pressure of 100 mmHg. The valve between the two chambers was opened rapidly, whereupon the pressure in chamber A fell within 14 seconds to 200 mmHg. The survival time of the mice in chamber A was determined to a maximum hypobaric exposure of 15 minutes. Effect of drug pretreatment on survival is calculated as the percent of the survival time of the drug-treated group as compared to saline- injected or vehicle-injected group. Control groups were tested twice, before and after each experiment and consisted of 12 to 16 mice, 4 per group. Each tested group always consisted of 4 mice in order to ensure a constant residual volume of oxygen in all tests. Survival time range of control mice was 108-180 seconds. The effect of each dose of the test drug was determined in duplicate, using a total of 8 mice, 4 per group. All drugs were administered i.p one hour prior to hypoxia. Positive reference drugs were sodium pentobarbital at a dose of 40 mg/kg, or diazepam at a dose of 10 mg.kg, given 0.5 hour prior to hypoxia. Results are shown in Table 2. Table 2. Effect of drug-treatment on relative survival time of mice at 200 mmHg, as percent of corresponding control Agent i.p dose mg/kg %protection ±SD relative to control saline/vehicle 0.5ml 100 Diazepam 10 430±59, p<0.001 5 249166, p<0.05 Pentobarbital 40 446±10.5, p<0.001 20 325±166, p<0.002 R(-)DeprenyI 100 102+75, (ns) 50 79±23, (ns) 10 97±70, (ns) (R)(+) PAI 100 358+179, p<0.001 mesylate 50 410±151, p<0.001 10 116±47, (ns) Agent i.p dose mg/kg %protection ±SD relative to control (S)(-)PAI mesylate 100 390±197, p<0.002 50 406±247, p<0.01 10 34±47 (ns) Example 3. Locomotor activity and brain infarct size in male Wistar rats after middle cerebral artery occlusion (MCA-O in the absence and presence of PAI enantiomers. A modification of the procedure described by Tamura et al was used (Tamura A, Graham D, McCulloch J, Teasdale GH (1981) J. Cereb. Blood Flow and Metab. 1 : 53- 60). Male Wistar rats (Olac England-Jerusalem) weighing 300-400g each, were anesthetized with a solution of Equitesine administered i.p. at a dose of 3 ml/kg. Equitesine consists of 13.5 ml sodium pentothal solution (60 mg/ml), 3.5 g chloral hydrate, 1.75 g MgS0 4 , 33 ml propylene glycol, 8.3 ml absolute alcohol, made up to 83 ml with distilled water. Surgery was performed with the use of a high magnification operating microscope, model SMZ-2B, type 102 (Nikon, Japan). In order to expose the left middle cerebral artery, a cut was made in the temporal muscle. The tip of the coronoid process of mandible was excised as well and removed with a fine rongeur. Craniectomy was made with a dental drill at the junction between the median wall and the roof of the inferotemporal fossa. The dura matter was opened carefully using a 27 gauge needle. The MCA was permanently occluded by microbipolar coagulation at low power setting, beginning 2-3 mm medial to the olfactory tract between its cortical branch to the rhinal cortex and the laterate striate arteries. After coagulation, the MCA was severed with microscissors and divided to ensure complete occlusion. Following this, the temporalis muscle was sutured and laid over the craniectomy site. The skin was closed with a running 3-0 silk suture. A sham craniectomy operation was performed on a parallel group of rats, but without cauterization of the MCA. During the entire surgical operation (20-25 min) in either group, body temperature was maintained at 37 to 38°C by means of a body-temperature regulator (Kyoristsu, Japan) 5 consisting of a self-regulating heating pad connected to a rectal thermistor. At 24 and 48 hours post surgery a neurological score was taken in order to assess the severity of the injury in the drug-treated rats with respect to their untreated controls. At 48 hours, the animals were anesthetized with Equitesine and the severity of the injury was visualized by 2,3,5-triphenyl tetrazolium chloride (TTC) staining. The volume of brain tissue incurring " damage following ischemia was determined. Drugs were administered as an i.p. injection in 0.3-0.4 ml distilled water, according to the following schedule: 5 3 mg/kg within 30min before surgery; 2 mg/kg 60 min after occlusion; 3 mg/kg within 20-24 hours after surgery. After 48 hours of ischemia induced by permanent occlusion, morphometric measurement of infarct volume was performed as follows by TTC staining. TTC 1% in saline was prepared 0 immediately before use and protected from exposure to light by aluminum foil wrap. MCA-O rats were deeply anesthetized and a 23 -gauge butterfly needle with an extended tubing and a 20 ml syringe was inserted into the ventricle via thoracotomy. The right atrium was incised to allow outflow of saline. Heparine 50 i.u. in saline was delivered until the perfusate was i - bloodless. A 30-ml TTC- filled syringe was exchanged for the saline syringe and TTC was injected into the left ventricle at a rate of 5 ml/min. Both perfusate solutions were administered at 37.5°C The brains were removed and immersed into 20 ml of 1% TTC contained in tightly closed glass vials. These were further placed for 2 hours in a water bath maintained at 37°C . The TTC solution was decanted, the brains removed, wiped dry and 0 placed into 10% buffered formalin solution for 3 days. Six coronal slices each 2 mm thick, 3,5,7,9,11 and 13mm distal from the frontal pole were obtained with a brain matrix (Harvard Apparatus, South Natick, MA). Infarction areas were measured with a video imaging and analyzer from both sides of the coronal slices and expressed in mm 2 . The volume of the infarcted region in mm 3 was calculated by taking the sum of the ischemic areas in all six slices . Infarct volumes are shown in Table 4 below. 5 Neurological score. The neurological score consists of the sum total of a series of ratings assigned to the performance of specific locomotor activities in a given rat. The scale runs from 0 (fully normal rats) to 13 (fully incapacitated rats). Most parameters are 0 rated as either 0 (normal), or 1 (incapacitated); others are graded. The following tests were used in the present study: General observational tests: hypoactivity; sedation, piloerection. 5 Motor reflex. Rats were lifted by the tail about 15 cm above the floor. Normal rats assume a posture in which they extend both forelimbs towards the floor and spread the hind limbs to the sides in a trapeze-like manner. MCAO, when severe, causes consistent flexion of the contralateral limb. 0 Motor ability. This is seen as the ability to grasp a rod 1 cm in diameter by the contralateral limb for 5-15 sec when the rat is left hanging on the rod through the arm pit. _ Motor coordination. Normal rats are able to walk up and down a beam, 5 cm wide placed at a moderate slant. Failure to walk the beam in either direction reveals some motor incoordination, lack of balance and limb weakness . Gait. Ability to restore normal position to either hind contralateral or fore contralateral limb when intentionally displaced while on a narrow beam . Balance. Ability to grasp and balance on a narrow beam 2 cm wide. Locomotor activit y . Total movements over a period of 15 min in an automated activity cage. Ratings assigned to each of the above parameters are given in Table 3 Table 3. Neurological scores assigned to each of 10 parameters of posture and locomotion :> Results The neurological severity score (NSS) and infarct volume were both significantly lower in the S(-) PAI treated rats than in saline-treated rats, as shown in Table 4 . 0 Table 4. Neurological severity score±SEM and brain infarct size±SEM in rats after permanent middle cerebral artery occlusion in the rat. Parameter S(-)PA1 treated saline treated p value Number of rats 24 24 Mean NSS±SEM after 24 hours 6.5±0.48 7.2+0.36 0.0543 Mean NSS±SEM after 48 hours 5.0±0.41 6.6±0.44 0.01 14 Mean infarct size±SEM, (mm 3 ) 200±13 240±1 1.2 0.0259 Percent improvement in NSS over saline 24 treated at 48 hours Under similar operating conditions, treatment with R(+)PAI resulted in about a 20% improvement in neurological score severity. Thus, neuroprotection in this particular model of neuronal insult was afforded almost equally by both the R- and S-enantiomers of the corresponding N-propargyl- 1-aminoindan. Example 4 Lack of effect of S-(-) -PAI on reserpine induced ptosis in rats Reserpine-induced ptosis and its reversal test. Reserpine causes depletion of catecholamine stores, especially norepinephrine. This effect in the live animal is manifested, among other things, in ptosis. Drugs that can prevent or inhibit reserpine- induced ptosis act either directly as noradrenergic agonists, or indirectly by decreasing or preventing the metabolic elimination of endogenous norepinephrine. MAO inhibitors belong to the latter category. Rats were premedicated with either saline, R(-)deprenyI or S(-)PAI i.p. and then, 2 hours later, were injected with reserpine 5mg/kg i.p. The degree of ptosis was scored on a 0 to 4 scale, where 4 represents eyes completely open, and 0 represents eyes completely closed. The data shown in Table 5 are consistent with the premise that S(-) - PAI does not cause an increase in endogenous norepinephrine concentrations. Table 5. Mean score of reserpine-induced ptosis (5mg/kg i.p.) with and without premedication with MAO inhibitors. Scores; taken 2 hours following reserpine administration Agent dose (n) Mean score (mg/kg) saline 12 0.86 R(-)Deprenyl 5 J 1.3 10 6 3.16 S(-)PAI 5 6 1.8 10 6 2.5 20 6 1.5 Example 5. Lack of pressor response of intravenous S(-)PAI in the anesthetized cat. Cats were anesthetized with i.v.nembutal 25 mg/kg. Anesthesia was maintained by additional injections of nembutal, 5mg./kg, as needed. The femoral artery was carmulated and connected to a Statham pressure transducer for blood pressure recordings on a Grass multichannel Polygraph. The femoral vein was carmulated for i.v. injection of drugs. The results are given in Table 6 and show that neither mean arterial blood pressure (MABP) nor heart rate (HR) were affected by intravenous S(-)PAI given in increasing doses up to a cumulative dose of 1 mg/kg and as long as 45-60 minutes after injection. * 5 Table 6. Changes in mean arterial blood pressure and heart rate in the nembutal anesthetized cat 45-60 min after intravenous injection of S(-)PAI Dose Change in MABP Change in HR (mmHg) (beats/min) 0 0.01 4 -8 0.03 7 -12 Dose Change in MABP Change in HR (mmHg) (beats/min) 0.01 -5 -10 0.03 5 8 0.1 -12 0 1.0 2 -5 Example 6. Lack of effect of S(- PAI on the pressor response to catecholamines in the cat. MAO inhibitors usually potentiate the pressor response to catecholamines because they block their metabolic elimination by the enzyme MAO, especially subtype A. Cats treated with S(-)PAI as described in Example 5 were further challenged with each of the following pressor agents: Phenylephrine, tyramine and norepinephrine. In each case, there was no significant potentiation of the pressor response after pretreatment with S(-)PAI at 1 mg/kg i.v. Results are given in Table 7. Table 7. Pressor response to intravenous catecholamines in the anesthetized cat, before and after pretreatment with S(-)PAI, given as an i.v.injection of 1 mg/kg Agent & dose (μg/kg) Δ mean arterial pressure Δ mean arterial pressure (mmHg) before S(-)PAI (mmHg) after S(-)PAI norepinephrine 0.02 8 12 0.05 23 32 0.10 31 23 0.20 46 46 phenylephrine 0.20 9 2 0.50 17 17 1.0 21 17 2.0 40 42 tyramine 2.0 11 3 5.0 19 9 Agent & dose (μg/kg) Δ mean arterial pressure Δ mean arterial pressure (mmHg) before S(-)PAI (mmHg) after S(-)PAI 10.0 26 28 20.0 42 39 Example 7. Lack of cardiovascular effects of S -.PAI in the conscious rat after acute oral administration. 0 A chronic-indwelling catheter was implanted in the caudal artery under light anesthesia with averteen. The animals were allowed to recover and were tested 24 hours after implantation. The catheter was connected to a Statham pressure transducer and blood pressure was recorded on a Grass multichannel Polygraph. During this period, the rat was kept in its home cage in order to minimize handling and undue manipulations known to 5 affect blood pressure. Two strains of rats were used: WKY rats and matching SHR (Spontaneously Hypertensive Rats) rats. WKY rats were from a local strain, weighing about 250g each. In n these, the maximum fluctuations of the mean arterial pressure (MAP) and heart rate (HR) were 8 mmHg and 49 beats per min, respectively, in the resting state. SHR rats were purchased from Charles River breeders, England. The animals were allowed to acclimatize and recover from the journey and were used at the age of three months, in order 5 to match their WKY controls. SHR hypertension develops gradually from the age of one month to the age of three months. At this stage, blood pressure is already elevated above normotensive levels. S(-)PAI was administered in a volume of lOml/kg. Blood pressure and heart rate were then 0 monitored for the duration of 45-60 minutes. Results are given in Table 8 and show that acute oral administration of S(-)PAI had no effect on either parameter in either strain of rats. Table 8. Cardiovascular effects of S(-)PAI in conscious rats 45-60 min after oral administration. Rat Strain Dose Change in MBAP Change in HR (mmHg) (beats/min) WKY 1 -9 70 -24 -130 2 -6 -20 9 70 5 0 0 0 0 0 10 0 0 20 0 0 -12 0 5 SHR 1 -16 -30 2 -12 0 5 13 0 -6 -40 10 4 0 0 Example 8. Lack of effect of S PAI on systolic blood pressure in SHR rats after chronic oral administration at 2 mg/kg/day. r> Spontaneously hypertensive rats, three month-old, were used. Each rat was given a daily dose of 2 mg/kg S(-) PAI in tap water 10 ml kg. Controls received an equivalent volume of tap water. Treatment lasted 14 days. During this period, systolic blood pressure was monitored on days 0, 4, 7 and 11, using a tail-cuff procedure. On day 14, systolic blood pressure was determined using the indwelling catheter procedure described in Example 7. The results are 0 given in Tables 9 and 10. Chronic oral treatment with S(-)PAI at 2 mg/kg/day had no effect on the intraindividual and interindividual profile of systolic blood pressure and heart rate. Table 9. Effect of S(-)PAI (2mg/kg p.o.) on systolic blood pressure and heart rate measured by tail cuff in SHR rats over a 2 week period. Day of Treatment Change in Mean Systolic Change in Heart rate Blood Pressure (mmHg) (beats/min) TAP WATER 0 169.55±7.73 374.09±37.17 4 177.82±9.08 403±23.3 7 177.67±10.21 392.67±24.66 1 1 178±8.65 371.25±27.22 S(-)PAI 0 166.88+6.1 1 404.13+32.86 4 168.5±12.8 394.5±37.43 7 172.13±14.62 394.38±24.47 11 167.43+14.23 408±40.04 Table 10. Cardiovascular effect of 2-week chronic oral treatment with S(-)PAI in SHR rats measured directly by an implanted catheter. Mean arterial blood pressure Systolic blood pressure Heart rate TAP WATER 107.65±9.59 138.37+13.41 404.55±49.82 S(-)PAI 107.88+5.35 140.79±6.55 366.11±34.99 Example 9 Lack of effect of S(-)PAI on body weight in SHR rats after chronic oral dosing at 2 mg/kg/day. The rats used in Example 8 above, were additionally monitored for weight gain/loss as an additional marker for the rate of food consumption. MAO inhibitors usually elevate central catecholamines which may depress appetite. Chronic treatment with S(-)PAI at 2 mg/kg/day had no effect on body weight throughout 14 days of treatment. Results are given in Table 1 1. Table 11. Effect on SHR rat body weight after 2 week chronic oral treatment with S(-)PAI. Day Weight (g) TAP WATER 0 317+32.64 7 302.22+35.17 14 312.89 S(-)PAI 0 294.13+32.06 7 292.25+28.47 14 307.33+24.13 Summary Examples 4-9 show that S(-)PAI has minimal or no effect on several MAO mediated effects. Example 10 Effect of S PAI following closed head injury (CHfi in mice The procedure for closed head injury followed was as described for rats in Shohami et al . (J Neurotrauma (1993) 10(2) 109-119) with changes as described. Animals: Male Sabra mice (Hebrew University strain) weighing 34-40g were used. They were housed in groups of 10 per cage, in a 12hr:12hr light:dark cycle. Food and water were provided ad libitium. Trauma was induced under anaesthesia. A longitudinal incision was performed in the skin covering the skull and the skin retracted to expose the skull. The head was fixed manually at the lower plane of the impact apparatus. A weight of 333g was delivered by an electric device from a distance of 3 cm to the left hemisphere, l-2mm lateral to the midline in the midcoronal plane. S-PAI was injected sub-cutaneously (1 mg/kg) once 15 min. after CHI. Assessment of Motor Function. Motor function and reflexes were evaluated in the injured mice at different times after closed head injury (CHI) using a neurological severity score (NSS*) as shown in Table 12 below, which is modified from that described for rats. One point was awarded for the lack of a tested reflex or for the inability to perform the tasks outline in the Table. The maximal score that can be reached at 1 hour post-CHI is 25 points and at later times, 21 points. The difference in NSS at lhr and at any other time reflects the spontaneous recovery, and is referred to as ΔNSS. A score of 15-19 at lhr denotes severe injury, 1 1-14 denotes moderate injury and less than 10 denotes mild injury. * The NSS assessed in this Example is different from that in Example 3, both in the parameters assessed and in the scoring system. Table 12 Neurological Severity Score for mice after Closed Head Injury Parameter Points at 1 hour post- Points at any other CHI time Inability to exit from a circle (30cm diameter) when left in its center for 30min for 60 min for >60 min 1 0 Loss of righting reflex for 10 second for 20 seconds for >30 seconds 1 Hemiplegia - inability of mouse to resist 1 forced changes in position Flexion of hind limb when lifted by tail 1 Inability to walk straight when placed on the 1 D floor Reflexes Pinna reflex 1 Corneal reflex 1 Startle reflex 1 Clinical grade Loss of seeking behaviour 1 0 Prostration 1 Parameter Points at 1 hour post- Points at any other CHI time Loss of reflexes Left forelimb 1 1 Right forelimb 1 1 Left hindlimb 1 1 Right hindlimb 1 1 — Functional test Failure in beam balancing task (0 5cm wide) for 20 seconds 1 1 for 40 seconds 1 1 for > 60 seconds 1 1 Failure in round stick balancing task (0 5 cm in diameter for 10 seconds 1 1 Failure in beam walking task 3 cm wide 1 1 2cm wide 1 1 1cm wide 1 1 Maximum Points 25 21 Assessment of Reference Memory Morris Water Maze Test the water maze consists of a circular aluminium pool, lm in diameter and 60cm in depth, filled with water to a depth of 17 5cm The hidden goal platform is a glass vessel (15cm diameter x 16 5cm height) placed upside down at a fixed location in the pool, 1cm below the surface of the water The water temperature is maintained at 24°C and the pool is always placed in the same position in the room to provide the same extra-maze cues Prior to CHI, mice were given 3 trials per day for 5 consecutive days to establish a baseline performance - measured as the latency to find the platform from the same start location Commencing 24hr after CHI mice were retested daily for 2 weeks in 3 trials per day Results Assessment of Motor Function Table 13 Change in Neurological Severity Score after Closed Head Injury in Mice Drug/dose N ΔNSS, 24 hr ΔNSS, 7 days ΔNSS, 14 days post-CHI post-CHI post-CHI Saline, 1 ml/kg 51 4 75±0 17 5 83±0 36 5 96±0 4 S(-)PAI, 1 mg/kg 16 5 06±0 25 7 19±0 28 7 88±0 36 Assessment of Reference Memory Figure 1 shows the reduction in latency for mice treated with S(-)PAI compared to saline treated controls after CHI. It appears that immediately post-CHI mice forget the location of the goal. Memory is enhanced following treatment with S(-)PAI, as compared to saline treated mice.

Claims: CLAIMS: 1. Pharmaceutical compositions for the treatment of a neurological disorder or neurotrauma or for improving memory in a patient, comprising a therapeutically effective amount of S-(-)-N-propargyl- 1-aminoindan or a pharmaceutically acceptable salt thereof as active ingredient, and a pharmaceutically active carrier. 2. A pharmaceutical composition according to claim 1 adapted for oral, rectal, intra-venous, transdermal or parcntcral administration. 3. A pharmaceutical composition according to claim 1 or 2 in unit dosage form comprising from about 1 mg to about 1000 mg of said active ingredient. 4. A pharmaceutical composition according to claim 3 comprising from about 10 mg to about 100 mg of said active ingredient. 5. A pharmaceutical composition according to any one of claims 1 to 4 comprising, as active ingredient the hydrochloridc, mesylate, esylate or sulfate salt of S-(-)-N-propargyl- 1-aminoindan. 6. A pharmaceutical composition according to any one of claims 1 to 5 for treating a neurological disorder or neurotrauma involving damage caused to the central or peripheral nervous system as a result of ischemic damage, stroke, hypoxia or anoxia, neurodegenerative diseases, Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage. 7. A pharmaceutical composition according to claim 1 for improving memory in a patient. 8. S-(-)-N-Propargyl- 1 -aminoindan or a pharmaceutically acceptable salt thereof for use as a medicament for the treatment of a neurological disorder or neurotrauma or for improving memory in a patient. 9. S-(-)-N-Propargyl- 1-aminoindan for the use according to claim 8, wherein the medicament is adapted for oral, rectal, intra-venous, transdermal or parcntcral administration. 10. S-(-)-N-Propargyl- 1-aminoindan for the use according to claim 8, wherein the medicament is administered at a dosage of from about 1 mg to about 100 mg. 11. The use according to claim 10, wherein the dosage is from about 10 mg to about 100 mg. 12. The hydrochloridc, mesylate, esylate or sulfate salt of S-(-)-N- propargyl-1 -aminoindan for the use according to claim 8. 13. The use according to claim 8, wherein the medicament is for the treatment of a neurological disorder or neurotrauma involving damage caused to the central or peripheral nervous system as a result of ischemic damage, stroke, hypoxia or anoxia, neurodegenerative diseases, Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage. 14. The use according to claim 8, wherein the medicament is for improving memory in a patient. 15. Use of S-(-)-N-propargyl-l -aminoindan or a pharmaceutically acceptable salt thereof in the manufacture of medicaments for the treatment of a neurological disorder or neurotrauma. 16. Use according to claim 15, wherein the medicaments are adapted for oral, rectal, intra-venous, transdermal or parcntcral administration. 17. Use according to claim 15, wherein the medicaments comprise S-(-)-N-propargyl- 1-aminoindan or a salt thereof at a dosage of from about 1 mg to about 1000 mg. 18. Use according to claim 17, wherein the dosage is from about 10 mg to about 100 mg. 19. Use according to claim 15 of the hydrochloridc, mcsylate, esylate, or sulfate salt of S-(-)-N-propargyl- 1-aminoindan. 20. Use according to claim 15, wherein the neurological disorder or neurotrauma involves damage caused to the central or peripheral nervous system as a result of ischemic damage, stroke, hypoxia or anoxia, neurodegenerative diseases, Parkinsons Disease, Alzhcimers Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage. 21. Use of S-(-)-N-propargyl- 1 -aminoindan or a pharmaceutically acceptable salt thereof as active ingredient in the manufacture of medicaments for improving memory in a patient. 22. A method of treating a patient suffering from neurotrauma comprising administering to said patient a therapeutically effective amount of (S)-N-propargyl- 1 -aminoindan or a pharmaceutically acceptable salt thereof. 23. A method of treating a patient afflicted with a neurodegenerative disease which comprises administering to said patient a therapeutically effective amount of (S)-N-propargyl- 1 -aminoindan or a pharmaceutically acceptable salt thereof. 24. A method of treating a patient afflicted with a neurotoxic injury which comprises administering to said patient a therapeutically effective amount of (S)-N-propargyl- 1 -aminoindan or a pharmaceutically acceptable salt thereof. 25. A method of treating a patient afflicted with brain ischemia which comprises administering to said patient a therapeutically effective amount of (S)-N-propargyl- 1 -aminoindan or a pharmaceutically acceptable salt thereof. 26. A method of treating a patient afflicted with a stroke which comprises administering to said patient a therapeutically effective amount of (S)-N-propargyl-l -aminoindan or a pharmaceutically acceptable salt thereof. 27. A method of treating a patient afflicted with neural injury following an episode of hypoxia or anoxia which comprises administering to said patient a therapeutically effective amount of (S)-N-propargyl-l - aminoindan or a pharmaceutically acceptable salt thereof. 28. A method of treating a patient afflicted with a head trauma injury which comprises administering to said patient a therapeutically effective amount of (S)-N-propargyl-l -aminoindan or a pharmaceutically acceptable salt thereof. 29. A method of treating a patient afflicted with a spinal trauma injury which comprises administering to said patient a therapeutically effective amount of (S)-N-propargyl- 1-aminoindan or a pharmaceutically acceptable salt thereof. 30. A method of preventing nerve death in a patient which comprises administering to said patient a therapeutically effective amount of (S)-N- propargyl- 1 -aminoindan or a pharmaceutically acceptable salt thereof. 31. A method of treating a patient afflicted with a memory disorder which comprises administering to said patient a therapeutically effective amount of (S)-N-propargyl- 1 -aminoindan or a pharmaceutically acceptable salt thereof.

Inventors: COHEN SASSON, FINBERG JOHN P M, LEVY RUTH, STERLING JEFF, YOUDIM MOUSSA B H, COHEN, SASSON, FINBERG, JOHN, P., M., LEVY, RUTH, STERLING, JEFF, YOUDIM, MOUSSA, B., H.
Applicants: COHEN SASSON, FINBERG JOHN P M, LEVY RUTH, STERLING JEFF, TECHNION RES & DEV FOUNDATION, TEVA PHARMA, YOUDIM MOUSSA B H, COHEN, SASSON, FINBERG, JOHN, P., M., LEVY, RUTH, STERLING, JEFF, TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., TEVA PHARMACEUTICAL INDUSTRIES LTD., YOUDIM, MOUSSA, B., H.
Application year: 1997
Main classification: A61K31
IPC codes: A61K31, A61P25, C07C211